Vicuron's Dalbavancin User Fee Date Extended To Sept. 21
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA extends user fee deadline for the lipoglycopeptide antibiotic by three months to review additional chemistry, manufacturing & controls data. Vicuron plans to amend the NDA for its antifungal anidulafungin in the second quarter.
You may also be interested in...
Pfizer’s Dalbavancin “Approvable”
FDA issued an "approvable" letter for Pfizer's lipoglycopeptide antibiotic dalbavancin Sept. 21, the agency said
Pfizer’s Dalbavancin “Approvable”
FDA issued an "approvable" letter for Pfizer's lipoglycopeptide antibiotic dalbavancin Sept. 21, the agency said
Vicuron Submits NDA For Additional Anidulafungin Indication
The invasive candidiasis/candidemia indication was spun off from a pending NDA for esophageal candidiasis.